Esomeprazole potassium salt
Based on 2 publication(s) in Google Scholar
Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research.
For research use only. We do not sell to patients.
- Purity: 98.98%
- CAS No.: 161796-84-5
- Formula: C17H18KN3O3S
- Molecular Weight:383.51
-
Storage:
-20°C, protect from light, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Esomeprazole potassium salt
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | IC50 |
>10 μM
Compound: 92309092
|
HARVARD: Cytotoxicity in HepG2 cell line
HARVARD: Cytotoxicity in HepG2 cell line
|
[PMID: 22586124] |
| HepG2 | IC50 |
0.291 μM
Compound: 92309092
|
HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells
HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells
|
[PMID: 22586124] |
Esomeprazole (25-100 µM; 20 hours; MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-468 cells
-
Concentration:25 µM, 50 µM, 75 µM, 100 µM
-
Incubation Time:20 hours
-
Result:Suppressed growth of triple-negative breast cancer cell in vitro in a dose-dependent manner.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury[2]
-
Dosage:30 mg/kg, 300 mg/kg
-
Administration:Oral gavage; daily; for 19 or 11 days
-
Result:Significantly inhibited the progression of fibrosis throughout the lungs of the animals.
Chemical Information
-
CAS No. 161796-84-5
-
Appearance Solid
-
Molecular Weight 383.51
-
Formula C17H18KN3O3S
-
Color White to light yellow
-
SMILES
O=[S@](C1=NC2=CC=C(OC)C=C2[N-]1)CC3=NC=C(C)C(OC)=C3C.[K+]
-
Synonyms
(S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Int Immunopharmacol
Inhibition of iron ion accumulation alleviates polystyrene nanoplastics-induced pulmonary fibroblast proliferation and activation. [Abstract]2025 Oct 30:164:115367. PMID: 40811949 -
Solvent & Solubility
DMSO : 33.33 mg/mL (86.91 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wayne Goh, et al. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17(3):439-46. [Content Brief]
[2]. Christina Nelson, et al. Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model. Front Pharmacol. 2017 Jan 26;8:16. [Content Brief]
[3]. Thomas J Johnson, et al. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15;59(14):1333-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6075 mL | 13.0375 mL | 26.0749 mL | 65.1873 mL |
| 5 mM | 0.5215 mL | 2.6075 mL | 5.2150 mL | 13.0375 mL | |
| 10 mM | 0.2607 mL | 1.3037 mL | 2.6075 mL | 6.5187 mL | |
| 15 mM | 0.1738 mL | 0.8692 mL | 1.7383 mL | 4.3458 mL | |
| 20 mM | 0.1304 mL | 0.6519 mL | 1.3037 mL | 3.2594 mL | |
| 25 mM | 0.1043 mL | 0.5215 mL | 1.0430 mL | 2.6075 mL | |
| 30 mM | 0.0869 mL | 0.4346 mL | 0.8692 mL | 2.1729 mL | |
| 40 mM | 0.0652 mL | 0.3259 mL | 0.6519 mL | 1.6297 mL | |
| 50 mM | 0.0521 mL | 0.2607 mL | 0.5215 mL | 1.3037 mL | |
| 60 mM | 0.0435 mL | 0.2173 mL | 0.4346 mL | 1.0865 mL | |
| 80 mM | 0.0326 mL | 0.1630 mL | 0.3259 mL | 0.8148 mL |
Esomeprazole potassium salt Related Classifications
HY-17021B Related Classifications
Powered by Bioz